The introduction of continuous glucose monitoring (CGM) systems for the care of people with either type 1 diabetes (T1D) or type 2 diabetes (T2D) treated with insulin has delivered significant improvements in glycaemia, with lower levels of glycated haemoglobin (HbA1c),1, 2 reduced hypoglycaemia,3, 4 along with improvements in patient‐reported distress and quality of life.5, 6. The gene discussed is INS; the disease is type 2 diabetes mellitus.